• Cytokinetics will present at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions in Chicago on Nov. 6, 2026.
• Two late-breaking oral presentations will examine aficamten’s effects on cardiac structure, function and patient-reported health status in nonobstructive hypertrophic cardiomyopathy.
• A poster presentation will address left ventricular systolic dysfunction during long-term aficamten therapy for obstructive hypertrophic cardiomyopathy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytokinetics Incorporated published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611020730PRIMZONEFULLFEED9867703) on November 02, 2026, and is solely responsible for the information contained therein.